These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 20349418)

  • 21. Uremic Toxins, Oxidative Stress, Atherosclerosis in Chronic Kidney Disease, and Kidney Transplantation.
    Wojtaszek E; Oldakowska-Jedynak U; Kwiatkowska M; Glogowski T; Malyszko J
    Oxid Med Cell Longev; 2021; 2021():6651367. PubMed ID: 33628373
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Hepatitis C virus and chronic progressive kidney disease].
    Kes P; Slavicek J
    Acta Med Croatica; 2009 Dec; 63(5):431-6. PubMed ID: 20198903
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Arterial Stiffness Assessed by Oscillometric Method in Kidney Transplant, Predialysis, and Dialysis Patients.
    Olczyk P; Małyszczak A; Gołębiowski T; Letachowicz K; Szymczak A; Mazanowska O; Krajewska M; Kusztal M
    Transplant Proc; 2020 Oct; 52(8):2337-2340. PubMed ID: 32359829
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chronic kidney disease after nonrenal solid-organ transplantation.
    Bloom RD; Reese PP
    J Am Soc Nephrol; 2007 Dec; 18(12):3031-41. PubMed ID: 18039925
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.
    Molony DA; Stephens BW
    Adv Chronic Kidney Dis; 2011 Mar; 18(2):120-31. PubMed ID: 21406297
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Treatment of bone disease in chronic kidney disease and in renal transplant recipients under K/DOQI clinical practice guidelines].
    Tokumoto T; Tanabe K; Toma H; Akiba T
    Clin Calcium; 2004 May; 14(5):710-8. PubMed ID: 15577031
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A rational guide to reducing fracture risk in dialysis patients.
    Toussaint ND; Elder GJ; Kerr PG
    Semin Dial; 2010; 23(1):43-54. PubMed ID: 20331818
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CANCER IN DIALYSIS PATIENTS.
    Wieliczko M; Pyrża M; Małyszko J
    Wiad Lek; 2020; 73(9 cz. 2):2068-2072. PubMed ID: 33148861
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of reduced immunosuppression after kidney transplant failure on risk of cancer: population based retrospective cohort study.
    van Leeuwen MT; Webster AC; McCredie MR; Stewart JH; McDonald SP; Amin J; Kaldor JM; Chapman JR; Vajdic CM; Grulich AE
    BMJ; 2010 Feb; 340():c570. PubMed ID: 20150194
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tuberculosis and chronic kidney disease: an emerging global syndemic.
    Romanowski K; Clark EG; Levin A; Cook VJ; Johnston JC
    Kidney Int; 2016 Jul; 90(1):34-40. PubMed ID: 27178832
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cumulative cancer incidence and mortality after kidney transplantation in Japan: A long-term multicenter cohort study.
    Imamura R; Nakazawa S; Yamanaka K; Kakuta Y; Tsutahara K; Taniguchi A; Kawamura M; Kato T; Abe T; Uemura M; Takao T; Kishikawa H; Nonomura N
    Cancer Med; 2021 Apr; 10(7):2205-2215. PubMed ID: 33314709
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study.
    Maisonneuve P; Agodoa L; Gellert R; Stewart JH; Buccianti G; Lowenfels AB; Wolfe RA; Jones E; Disney AP; Briggs D; McCredie M; Boyle P
    Lancet; 1999 Jul; 354(9173):93-9. PubMed ID: 10408483
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The efficacy and safety of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors in chronic kidney disease, dialysis, and transplant patients.
    Olyaei A; Greer E; Delos Santos R; Rueda J
    Clin J Am Soc Nephrol; 2011 Mar; 6(3):664-78. PubMed ID: 21393488
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Similar risks for chronic kidney disease in long-term survivors of myeloablative and reduced-intensity allogeneic hematopoietic cell transplantation.
    Al-Hazzouri A; Cao Q; Burns LJ; Weisdorf DJ; Majhail NS
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):658-63. PubMed ID: 18489991
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chronic kidney disease following liver transplantation: a South Australian experience.
    Ramachandran J; Juneja R; John L; Dutta AK; Chen JW; Woodman RJ; Wigg AJ
    Transplant Proc; 2010 Nov; 42(9):3644-6. PubMed ID: 21094832
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Managing cancer risk and decision making after kidney transplantation.
    Webster AC; Wong G; Craig JC; Chapman JR
    Am J Transplant; 2008 Nov; 8(11):2185-91. PubMed ID: 18782291
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Higher mortality risk among kidney transplant recipients than among estimated glomerular filtration rate-matched patients with CKD-preliminary results.
    Cheddani L; Liabeuf S; Essig M; Snanoudj R; Jacquelinet C; Kerleau C; Metzger M; Balkau B; Drüeke TB; Hourmant M; Massy ZA;
    Nephrol Dial Transplant; 2021 Jan; 36(1):176-184. PubMed ID: 32162656
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Renal Tumor in Allogeneic Kidney Transplant Recipient.
    Bieniasz M; Chmura A; Kwapisz M; Czerwińska M; Kieszek R; Domagała P; Wszoła M; Serwańska-Świętek M; Górnicka B; Durlik M; Pączek L; Kwiatkowski A
    Transplant Proc; 2016 Jun; 48(5):1849-54. PubMed ID: 27496506
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incidence and consequences of acute kidney injury in kidney transplant recipients.
    Mehrotra A; Rose C; Pannu N; Gill J; Tonelli M; Gill JS
    Am J Kidney Dis; 2012 Apr; 59(4):558-65. PubMed ID: 22226565
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cancer risk in patients on dialysis and after renal transplantation.
    Birkeland SA; Løkkegaard H; Storm HH
    Lancet; 2000 May; 355(9218):1886-7. PubMed ID: 10866449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.